著者
Toshifumi Nanjo Takaomi Fukuhara Naoko Kameshima Daijiro Yanagisawa Shino Shimizu Takeshi Shimizu Akihiko Shiino Hiroyasu Akatsu Takayuki Yamamoto Ikuo Tooyama
出版者
Japan Brain Science society
雑誌
脳科学誌 (ISSN:13415301)
巻号頁・発行日
vol.44, pp.5-23, 2014-12-30 (Released:2017-06-01)

Previous studies have reported that β-amyloid peptides (Aβ) are observed in the nasal mucosa of postmortem human samples. In a mouse model of Alzheimer's disease (AD), nasal Aβ levels positively correlate with insoluble Aβ levels in the brain. However, it is difficult to measure Aβ content in human nasal smears. Here we report a novel and sensitive method of measuring Aβ42 content in the human nasal cavity and its application in normal human volunteers. We collected nasal smears by cotton swab from the mucosa of the inferior nasal concha and common nasal meatus of 26 normal volunteers with an age range of 23-78 years. The swabs were placed in microtubes and extracted with pure water. Extract solution was removed from each sample for protein assay and the remaining sample was added with formic acid, incubated at 70℃ for one hour, and then centrifuged in a centrifugal filter device to remove larger protein complexes and cellular debris. The filtrates were concentrated and then buffered before Aβ42 concentrations were measured using a commercially available ELISA kit. Samples from five volunteers were also assayed for Aβ42 content without pretreatment. Our novel method for collecting and assaying nasal mucosal smears enabled us to measure Aβ42 content in both the inferior nasal concha and the common nasal meatus of all cases examined, despite the levels being under detection limits (0.1 pmol/L) without pretreatment. There was significantly more Aβ42 content per gram of total protein in the inferior nasal concha (12.37 ± 5.98 pmol/g) than in the common nasal meatus (3.58 ± 1.94 pmol/g; P < 0.001). Thus, this method would be useful for AD screening.
著者
Toshifumi Nanjo Takaomi Fukuhara Naoko Kameshima Daijiro Yanagisawa Shino Shimizu Takeshi Shimizu Akihiko Shiino Hiroyasu Akatsu Takayuki Yamamoto Ikuo Tooyama
出版者
Japan Brain Science society
雑誌
脳科学誌 (ISSN:13415301)
巻号頁・発行日
vol.42, pp.5-20, 2013-09-30 (Released:2017-06-01)

Previous studies reported that β-amyloid peptides (Aβ) were observed in nasal mucosa of postmortem human samples. In the model mouse of Alzheimer's disease (AD), nasal Aβ levels positively correlate with insoluble Aβ levels in the brain. However, it is difficult to measure Aβ content in human nasal smears. Here we have reported a novel and sensitive method of measuring Aβ42 content in the human nasal cavity. We collected nasal smears by cotton swab from the mucosa of the inferior nasal concha and common nasal meatus of 13 normal volunteers with an age range of 30-78 years. The swabs were put into microtubes and the protein content extracted with 700 μL of 80% formic acid. Ten microliters of the extract solution was removed from each sample to assay protein levels. The remaining 690 μL was incubated at 70℃ for one hour, transferred to a centrifugal filter device, and centrifuged for one hour at 14000 g to remove larger protein complexes and cellular debris. The filtrates were concentrated to 20 μL, and then neutralized by adding 480 μL of 1 M Tris. Finally, the Aβ42 protein concentrations were measured using a commercially available ELISA kit, with the samples from five volunteers assayed for Aβ42 content without pretreatment. Our novel method for collecting and assaying nasal mucosal smears enabled us to measure Aβ42 content in both the inferior nasal concha and the common nasal meatus of all cases examined here, despite the levels being under detection limits (0.5 pmol/L) without pretreatment. The mean levels of Aβ42 per total protein in the inferior nasal concha and common nasal meatus of normal controls were 6.24 ± 3.70 fmol/g and 2.10 ± 0.77 fmol/g, respectively. Thus, there was significantly more Aβ42 content per total protein in the inferior nasal concha than in the common nasal meatus (P<0.01). Thus, this method would be useful for AD screening.
著者
Osamu MORI Hirotaka SAWADA Ryu FUNASE Mutsuko MORIMOTO Tatsuya ENDO Takayuki YAMAMOTO Yuichi TSUDA Yasuhiro KAWAKATSU Jun'ichiro KAWAGUCHI Yasuyuki MIYAZAKI Yoji SHIRASAWA IKAROS Demonstration Team and Solar Sail Working Group
出版者
THE JAPAN SOCIETY FOR AERONAUTICAL AND SPACE SCIENCES
雑誌
TRANSACTIONS OF THE JAPAN SOCIETY FOR AERONAUTICAL AND SPACE SCIENCES, AEROSPACE TECHNOLOGY JAPAN (ISSN:18840485)
巻号頁・発行日
vol.8, no.ists27, pp.To_4_25-To_4_31, 2010 (Released:2011-06-14)
参考文献数
1
被引用文献数
19 40

The Japan Aerospace Exploration Agency (JAXA) will make the world's first solar power sail craft demonstration of photon propulsion and thin film solar power generation during its interplanetary cruise by IKAROS (Interplanetary Kite-craft Accelerated by Radiation Of the Sun). The spacecraft deploys and spans a membrane of 20 meters in diameter taking the advantage of the spin centrifugal force. The spacecraft weighs approximately 310kg, launched together with the agency's Venus Climate Orbiter, AKATSUKI in May 2010. This will be the first actual solar sail flying an interplanetary voyage.
著者
Hisashi Sasaki Yoshifumi Kimizuka Hiraku Ogata Yosuke Okada Shinichiro Ota Tomoya Sano Chie Watanabe Yohei Maki Takayuki Yamamoto Yoichi Tagami Jun Miyata Nobuyoshi Hayashi Yuji Fujikura Akihiko Kawana
出版者
The Japanese Society of Internal Medicine
雑誌
Internal Medicine (ISSN:09182918)
巻号頁・発行日
pp.3002-19, (Released:2019-07-10)
参考文献数
14
被引用文献数
6

Dasatinib-related chylothorax is a rare adverse event, and the mechanism underlying its occurrence is still not fully understood. We herein report the case of a 73-year-old woman with chronic myeloid leukemia (CML) who developed dasatinib-related chylothorax refractory to conventional treatments, except for steroids. To the best of our knowledge, this is the first case of dasatinib-related chylothorax which was successfully controlled by combining diuretics with the Japanese herbal medicine "Goreisan." "Goreisan" is known to inhibit aquaporin channels and regulate the water flow. Our findings showed that "Goreisan" is an effective treatment option for uncontrollable dasatinib-related chylothorax.
著者
Morihiko Oya Takao Tanimoto Takayuki Yamamoto Yukiya Hakozaki
出版者
一般社団法人 日本内科学会
雑誌
Internal Medicine (ISSN:09182918)
巻号頁・発行日
vol.54, no.14, pp.1803-1808, 2015 (Released:2015-07-15)
参考文献数
30
被引用文献数
8

A 33-year-old previously healthy man injured his gums and subsequently developed dyspnea and fever. A chest X-ray showed nodules and infiltrates in both lungs, and the patient was initially diagnosed with pneumonia and administered meropenem hydrate, although his symptoms did not improve. A blood culture identified Fusobacterium necrophorum, and thrombophlebitis in the internal jugular vein of the neck was observed on computed tomography and ultrasound scans. We replaced the meropenem with clindamycin, sulbactam/ampicillin and metronidazole, and the patient's symptoms improved.